Secukinumab Bests Ustekinumab in Psoriasis CLEAR Study Save

The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Using the highest benchmark (PASI-90) as the primary endpoint, secukinumab (79.0%) was superior to ustekinumab (57.6%) at week 16. Even at the week 4 time point, secukinumab had better PASI-75 outcomes than ustekinumab (50.0% versus 20.6%). Safety outcomes were similar, there were no deaths and serious adverse events only affected 3% of each group.
Such head-to-head trials will be pivotal to patients and physicians in managing moderate to severe psoriasis.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.